Question explored with the scientific record
Side effects of proton pump inhibitors
The short version: PPIs are linked to real harms in long-term users, but most of that evidence is observational, and the strongest randomized trial found a possible mortality signal rather than proof.
The clearest signal is not the one most people worry about. A large randomized trial in ventilated ICU patients (PEPTIC, about 26,800 people) found PPIs prevented more stomach bleeding than the alternative drug class but showed a possible mortality signal, with an absolute risk difference of about 0.93% higher with PPIs [2]. That is a randomized comparison, which matters more than any observational study here.
The rest of the harm list is mostly observational, and the numbers are modest. A five-cohort analysis of over 2 million people tied PPI use to 15 of 30 major diseases, with hazard ratios from 1.12 to 1.54, and found risk rose with longer use [9]. A veterans study estimated 45 excess deaths per 1,000 PPI users over 10 years versus H2 blockers [8]. Reviews link long-term use to low magnesium, kidney disease, fractures, B12 deficiency, and dementia, but a critical review notes most of these are not proven causal and likely reflect confounding [4][7][5].
| Harm | Comparison | Finding |
|---|---|---|
| Death (ICU trial) | PPI vs H2 blocker | 0.93% higher absolute risk [2] |
| Death (veterans) | PPI vs H2 blocker | 45 per 1,000 over 10 years [8] |
| Low magnesium | Long-term users vs non | 19.4% vs 13.5% [6] |
| C. diff (RCTs) | PPI vs placebo | No significant increase [1] |
Notice the C. diff story: randomized trials found no significant increase [1], while observational meta-analyses found roughly double the risk [3][4]. That gap is what confounding looks like.
My call: for short-term, clearly indicated use the case for harm is weak; for years of open-ended use, the observational signal is consistent enough to justify the lowest effective dose and periodic review. Confidence: moderate.
Sources used 9
-
Proton pump inhibitors are not associated with an increased risk of Clostridioides difficile infection: a systematic review and meta-analysis of randomized controlled trials
This is a comprehensive PRISMA-guided meta-analysis of randomized controlled trials that finds proton pump inhibitors (PPIs) do not significantly increase the risk of Clostridioides difficile infection (CDI) compared with placebo or several acid-suppressive comparators in adults…
DOI: 10.1080/19490976.2025.2562341 -
Stress ulcer prophylaxis in ICU patients: Answers and questions from the PEPTIC trial
This editorial discusses the PEPTIC trial, a large pragmatic cluster-crossover RCT comparing proton pump inhibitors vs histamine-2 receptor blockers for stress ulcer prophylaxis in invasively ventilated ICU patients, finding no overall mortality difference but a possible mortali…
DOI: 10.1016/j.accpm.2020.03.005 -
Proton pump inhibitor (PPI) administration and Clostridioides difficile infection - is this a real clinical problem? A critical review of the literature
This critical review of six meta-analyses concludes that PPI use is associated with a statistically significant increase in Clostridioides difficile infection risk in adults and children, but the relationship remains controversial because of confounding and conflicting trial evi…
DOI: 10.12775/jehs.2023.48.01.001 -
Adverse effects of proton-pump inhibitor use in older adults: a review of the evidence
This review synthesizes observational evidence that long-term proton-pump inhibitor use in older adults is associated with increased risks of bone fractures, Clostridium difficile infection, community-acquired pneumonia, vitamin B12 deficiency, kidney disease, and dementia, thou…
DOI: 10.1177/2042098617715381 -
Adverse Effects Associated With Proton Pump Inhibitors
This JAMA Internal Medicine editorial synthesizes recent observational evidence on adverse effects associated with proton pump inhibitor use, highlighting risks of chronic kidney disease, hypomagnesemia, Clostridium difficile infection, pneumonia, and fractures, and urging cauti…
DOI: 10.1001/jamainternmed.2015.7927 -
Hypomagnesemia as an Underrecognized Adverse Effect of Long-Term Proton Pump Inhibitor Therapy: Literature review
This narrative review consolidates evidence that long-term proton pump inhibitor therapy causes hypomagnesemia by raising intestinal luminal pH and impairing TRPM6/TRPM7-mediated magnesium absorption, and argues that routine magnesium monitoring in long-term PPI users is warrant…
DOI: 10.12775/jehs.2026.95.73646 -
Complications of Proton Pump Inhibitor Therapy
A critical, Hill criteria–based review assessing proposed long‑term proton pump inhibitor (PPI) safety concerns, finding that most associations are not proven causal and are likely influenced by residual confounding, while emphasizing PPI benefits when indicated and the need for…
DOI: 10.1053/j.gastro.2017.04.047 -
Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study
In US veterans, new PPI use was associated with 45.20 excess all-cause deaths per 1000 users over 10 years and excess mortality due to cardiovascular disease, chronic kidney disease, and upper gastrointestinal cancer, including among patients without documented indications.
DOI: 10.1136/bmj.l1580 -
Individualized prevention of proton pump inhibitor related adverse events by risk stratification
In five prospective cohorts (2,079,724 participants), proton pump inhibitor use was associated with increased risk of 15 of 30 leading global-burden diseases, with dose-response relationships and risk stratification concentrating PPI-attributable cases in high baseline-risk indi…
DOI: 10.1038/s41467-024-48007-8